Compare LNSR & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNSR | SPRO |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.7M | 67.0M |
| IPO Year | 2005 | 2017 |
| Metric | LNSR | SPRO |
|---|---|---|
| Price | $4.49 | $0.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $11.00 | $5.33 |
| AVG Volume (30 Days) | 68.0K | ★ 333.8K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ 0.56 | N/A |
| Revenue | $58,435,000.00 | ★ $66,802,000.00 |
| Revenue This Year | $4.22 | N/A |
| Revenue Next Year | $19.43 | N/A |
| P/E Ratio | $8.38 | ★ N/A |
| Revenue Growth | 9.24 | ★ 39.24 |
| 52 Week Low | $4.30 | $0.81 |
| 52 Week High | $12.94 | $3.08 |
| Indicator | LNSR | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 29.73 | 24.11 |
| Support Level | $4.30 | N/A |
| Resistance Level | $6.29 | $1.27 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 9.12 | 1.76 |
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia (excluding South Korea), South Korea, and Other.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.